As a sequel to last year's Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics Inc. that rendered isolated DNA ineligible for patenting, the Federal Circuit Wednesday struck down six more Myriad patent claims related to the BRCA 1 and 2 genes.